AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

A novel EGFR-tyrosine kinase inhibitor (TKI), osimertinib, has marked efficacy in patients with EGFR-mutated lung cancer. However, some patients show intrinsic resistance and an insufficient response to osimertinib. This study showed that osimertinib stimulated AXL by inhibiting a negative feedback...

全面介绍

Saved in:
书目详细资料
Main Authors: Hirokazu Taniguchi, Tadaaki Yamada, Rong Wang, Keiko Tanimura, Yuta Adachi, Akihiro Nishiyama, Azusa Tanimoto, Shinji Takeuchi, Luiz H. Araujo, Mariana Boroni, Akihiro Yoshimura, Shinsuke Shiotsu, Isao Matsumoto, Satoshi Watanabe, Toshiaki Kikuchi, Satoru Miura, Hiroshi Tanaka, Takeshi Kitazaki, Hiroyuki Yamaguchi, Hiroshi Mukae, Junji Uchino, Hisanori Uehara, Koichi Takayama, Seiji Yano
格式: Artigo
语言:英语
出版: 2019
在线阅读:https://doi.org/10.1038/s41467-018-08074-0
https://www.nature.com/articles/s41467-018-08074-0.pdf
标签: 添加标签
没有标签, 成为第一个标记此记录!

因特网

https://doi.org/10.1038/s41467-018-08074-0
https://www.nature.com/articles/s41467-018-08074-0.pdf

相似书籍